Business
Agreement with St. Jude Children's Hospital
Agreement with St. Jude Children's Hospital.
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n \n \n \n RNS Number : 0858S\n IQ-AI Limited\n 11 November 2021\n \n \n \n \n 11 November 2021\n \n \n IQ-AI Ltd\n \n \n (\"IQ-AI\" or the \"Company\")\n \n \n \n \n Imaging Biometrics and St. Jude Children's Hospital Enter Agreement\n IB Zero G™ Technology May Benefit Imaging in Paediatric Patients\n \n Milwaukee - 11 November 2021: IQ-AI Limited (LSE: IQAI) (OTCQB: IQAIF), a developer of medical image processing platforms that have led to effective therapeutic strategies for brain tumor and other patients, and St. Jude Children's Hospital (Memphis, TN), have entered into a Data Use Agreement. The Agreement is a specific type of agreement required under the Health Insurance Portability and Accountability Act (HIPPA) Privacy Rule. It will provide Imaging Biometrics (IB) access to paediatric imaging datasets for use in the development of its patented, artificial intelligence (AI) technology, IB Zero G.\n St. Jude Children's Hospital is the only National Cancer Institute (NCI)-designated Comprehensive Care Centre devoted solely to children. It has received the NCI's highest ranking of \"exceptional\" and has treated children from all 50 US states and from around the world.\n Through this Agreement, IB will have access to a wide array of magnetic resonance (MR) datasets acquired in children of all ages. Diverse and accurately labelled (annotated) data are critical for developing and refining AI models. High quality data enables AI models to accurately analyze new, incoming, real-world image datasets. IB Zero G will use this data to generate synthetic contrast-enhanced images for paediatric neuro examinations.\n Gadolinium Based Contrast Agents (GBCAs) have been used clinically in MRI examinations for decades and provide invaluable diagnostic information. In 2006, safety concerns were raised for GBCA use in patients due to the causative effect in a condition called nephrogenic systemic fibrosis (NSF). Since then, the awareness and understanding about GBCA use has escalated worldwide. More recently, it was found that repeated exposure of GBCAs result in its retention throughout the body. While the long-term adverse side effects are not known, the detrimental concerns for critical periods of life and especially on rapidly developing bone or brain, remain.\n \"This Agreement will accelerate the development and comme...